Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 8 | 545 | 44% |
| 2020 | 8 | 504 | 47% |
| 2021 | 19 | 824 | 51% |
| 2022 | 20 | 1,028 | 54% |
| 2023 | 15 | 1,093 | 57% |
| 2024 | 20 | 1,201 | 59% |
| 2025 from claims | – | 1,436 1,318–1,520 | 59% |
| 2026 forecast | – | 1,583 1,393–1,827 | 60% |
| 2027 forecast | – | 1,744 1,491–2,078 | 60% |
| 2028 forecast | – | 1,921 1,603–2,352 | 61% |
| 2029 forecast | – | 2,115 1,727–2,652 | 61% |
| 2030 forecast | – | 2,328 1,865–2,984 | 62% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 69% of the cases CMS names in Texas; 14 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 18% inpatient hospital, 23% hospital outpatient, 31% surgery center, 27% office. The share outside the hospital has moved +59 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 18 | 1,158+12%/yr | +12%/yr | 0.5 | 66% | 2,840 in 2030+16%/yr |
| Oklahoma | 9 | 370+24%/yr | +24%/yr | 0.7 | 54% | 610 in 2030+8.7%/yr |
| Georgia | 7 | 300+10%/yr | +10%/yr | 0.3 | 67% | 370 in 2030+3.5%/yr |
| South Carolina | 3 | 206+39%/yr | +39%/yr | 0.3 | 14% | 340 in 2030+8.7%/yr |
| Tennessee | 3 | 175+24%/yr | +24%/yr | 0.2 | 16% | 320 in 2030+11%/yr |
| Virginia | 3 | 167+8.3%/yr | +8.3%/yr | 0.1 | 0% | 390 in 2030+15%/yr |
| North Carolina | 3 | 167+8.3%/yr | +8.3%/yr | 0.1 | 13% | 340 in 2030+13%/yr |
| Maryland | 2 | 164+22%/yr | +22%/yr | 0.2 | 0% | 290 in 2030+10%/yr |
| Louisiana | 1 | 124+13%/yr | +13%/yr | 0.3 | 0% | 350 in 2030+19%/yr |
| Alabama | 1 | 100+11%/yr | +11%/yr | 0.2 | 0% | 60 in 2030−8.8%/yr |
| Kentucky | 2 | 100−6.4%/yr | −6.4%/yr | 0.2 | 0% | 170 in 2030+8.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 195 | 8,404−6.2%/yr | −6.2%/yr | 3.81.2× | 4% | 9,180 in 2030+1.5%/yr |
| Lumbar fusion | 196 | 8,171+0.1%/yr | +0.1%/yr | 3.71.2× | 4% | 9,840 in 2030+3.2%/yr |
| Cervical fusion & disc arthroplasty | 91 | 4,236−3.4%/yr | −3.4%/yr | 1.91.1× | 3% | 4,580 in 2030+1.3%/yr |
| Kyphoplasty & vertebroplasty | 43 | 3,866−5.3%/yr | −5.3%/yr | 1.81.0× | 26% | 3,550 in 2030−1.4%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
SI-BONE leads with 40% of company spending on these surgeons in 2025, −14 pts on 2024.
In 2025, 12 companies reported engagement with Texas’s surgeons worth $187K in consulting, speaking, meals and travel tied to these products, about $9,346 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.